JP2024530007A5 - - Google Patents
Info
- Publication number
- JP2024530007A5 JP2024530007A5 JP2024506546A JP2024506546A JP2024530007A5 JP 2024530007 A5 JP2024530007 A5 JP 2024530007A5 JP 2024506546 A JP2024506546 A JP 2024506546A JP 2024506546 A JP2024506546 A JP 2024506546A JP 2024530007 A5 JP2024530007 A5 JP 2024530007A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- anxiety
- composition according
- personality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230237P | 2021-08-06 | 2021-08-06 | |
| US63/230,237 | 2021-08-06 | ||
| US202163240113P | 2021-09-02 | 2021-09-02 | |
| US63/240,113 | 2021-09-02 | ||
| US202163255706P | 2021-10-14 | 2021-10-14 | |
| US63/255,706 | 2021-10-14 | ||
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US63/325,757 | 2022-03-31 | ||
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| US63/328,343 | 2022-04-07 | ||
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530007A JP2024530007A (ja) | 2024-08-14 |
| JP2024530007A5 true JP2024530007A5 (https=) | 2025-08-06 |
Family
ID=85156410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506546A Pending JP2024530007A (ja) | 2021-08-06 | 2022-08-01 | 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US11707446B2 (https=) |
| EP (1) | EP4380588A4 (https=) |
| JP (1) | JP2024530007A (https=) |
| KR (1) | KR20240072133A (https=) |
| AU (1) | AU2022325135A1 (https=) |
| CA (1) | CA3227360A1 (https=) |
| IL (1) | IL310334A (https=) |
| MX (1) | MX2024001654A (https=) |
| TW (1) | TW202327571A (https=) |
| WO (1) | WO2023015154A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254190A2 (en) * | 2023-06-06 | 2024-12-12 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12295937B2 (en) | 2021-08-06 | 2025-05-13 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12343326B2 (en) | 2021-08-06 | 2025-07-01 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| KR20240165982A (ko) * | 2022-03-31 | 2024-11-25 | 트랜센드 테라퓨틱스 인코퍼레이티드 | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
-
2022
- 2022-08-01 MX MX2024001654A patent/MX2024001654A/es unknown
- 2022-08-01 IL IL310334A patent/IL310334A/en unknown
- 2022-08-01 JP JP2024506546A patent/JP2024530007A/ja active Pending
- 2022-08-01 AU AU2022325135A patent/AU2022325135A1/en active Pending
- 2022-08-01 CA CA3227360A patent/CA3227360A1/en active Pending
- 2022-08-01 WO PCT/US2022/074369 patent/WO2023015154A1/en not_active Ceased
- 2022-08-01 KR KR1020247007349A patent/KR20240072133A/ko active Pending
- 2022-08-01 EP EP22854040.7A patent/EP4380588A4/en active Pending
- 2022-08-05 TW TW111129588A patent/TW202327571A/zh unknown
- 2022-08-15 US US17/887,962 patent/US11707446B2/en active Active
-
2023
- 2023-06-28 US US18/215,547 patent/US12059402B2/en active Active
- 2023-11-02 US US18/386,337 patent/US11969407B2/en active Active
-
2024
- 2024-05-09 US US18/659,413 patent/US12233046B2/en active Active
-
2025
- 2025-01-16 US US19/024,616 patent/US20250255846A1/en active Pending
- 2025-12-04 US US19/409,215 patent/US20260083699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530007A5 (https=) | ||
| Yasuda et al. | Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia | |
| AU2022221494A1 (en) | Methods and compositions for treating aging-associated impairments | |
| Baltzan et al. | Dream enactment behavior: review for the clinician | |
| AU2023201479A1 (en) | Anti-adrenomedullin (ADM) binder for use in therapy or prevention of symptoms of illness | |
| Zurawski et al. | Multiple sclerosis re-examined: essential and emerging clinical concepts | |
| Bain et al. | Call-Fleming syndrome: headache in a 16-year-old girl | |
| Verster | Melatonin and its agonists, circadian rhythms and psychiatry | |
| M Dieleman | Corticosteroids for the inflammatory response to cardiopulmonary bypass: an update | |
| Chen et al. | Fucosyltransferase 9 promotes neuronal differentiation and functional recovery after spinal cord injury by suppressing the activation of Notch signaling: Fucosyltransferase 9 promotes neuronal differentiation | |
| Vincent et al. | Treatment of epistaxis in Osler-Weber-Rendu disease by bevacizumab nasal spray. The EROSB study: Determining the effective dose | |
| JP2025510790A5 (https=) | ||
| Bennet et al. | The neural and vascular effects of killed Su-Streptococcus pyogenes (OK-432) in preterm fetal sheep | |
| Keilhoff et al. | Minocycline neuroprotection in a rat model of asphyxial cardiac arrest is limited | |
| Smetana et al. | Drugs acting on the cerebral and peripheral circulations | |
| Podlecka-Piętowska et al. | COVID-19 in neuromyelitis optica spectrum disorder patients in Poland | |
| Kasturi | Complement C1q in psychiatric disorder: elucidating correlations to synaptic pathology | |
| Vanaie et al. | The effect of sneezing on the reduction of infarct volume and the improvement of neurological deficits in male rats | |
| Chen et al. | Optic neuropathy after COVID-19 | |
| Kara et al. | Panic disorder developed by varenicline use | |
| HK40083955A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| Sleeman et al. | Autoimmune neurological disease after cardiac surgery | |
| Li et al. | Effects of manual acupuncture on microglial polarization and the Sirt1/NF-κB pathway in a rat model of post-stroke depression | |
| HK40085254A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| Mbaluka et al. | E-104 Young man with osteogenesis imperfecta presenting with acute stroke from carotid dissection and subsequent contralateral pseudoaneurysm |